Plus   Neg

Teledyne Now Expects FY20 EPS To Be Lower Than Initial Outlook - Quick Facts

Announcing preliminary results for the first quarter of fiscal 2020 on Monday, Teledyne Technologies Inc. (TDY) said it expects to achieve record first quarter sales and earnings per share. Sales are expected to increase over 5%, including positive organic growth, to about $785 million.

The company also expects earnings first quarter to increase to a range of $2.10 to $2.15 per share, compared to $2.02 per share in the first quarter of 2019. Orders also exceeded sales in each month of the first quarter, resulting in record backlog of approximately $1.8 billion.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $2.29 per share on sales of $796.87 billion for the quarter. Analysts' estimates typically exclude special items.

However, given likely reductions in customer capital expenditures, the company currently expects a substantial change in demand in the second quarter for some of Teledyne's commercial businesses, especially those serving North America and Europe-based customers.

Due to the current environment, Teledyne's full year earnings outlook will decrease from the prior outlook issued January 22, 2020.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Billionaire Warren Buffett's Berkshire Hathaway reported a profit for the second-quarter that increased 87 percent from last year, as the value of its investment portfolio increased with the stock market. But it took about $10 billion write down on the value of its Precision Castparts aircraft parts unit due to the impact of the COVID-19 pandemic. Operating profit declined 10 percent. Twitter has had preliminary talks with TikTok's Chinese owner ByteDance to buy the U.S. operations of the video-sharing app, the Wall Street Journal reported citing people familiar with the matter. Meanwhile, Microsoft has been the only company so far to say publicly it is pursuing TikTok. Pfizer said Friday it reached a multi-year deal with Gilead Sciences to manufacture and supply Gilead's investigational antiviral remdesivir for COVID-19 patients.
Follow RTT